TUTOR: A MULTICENTER, PHASE 1 TRIAL OF TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER

被引：0
|
作者：
Ahluwalia, M. S. [1 ,2 ]
Ozair, A. [1 ,3 ]
Bardhan, M. [1 ]
Bellur, S. S. [1 ]
Perche, D. C. [1 ]
Starosciak, A. K. [1 ]
Khosla, A. A. [1 ]
Leon-Ariza, D. S. [1 ]
Rubens, M. [1 ]
Odia, Y. [1 ]
Mehta, M. P. [1 ,2 ]
Kotecha, R. R. [1 ,2 ]
McDermott, M. W. [2 ,4 ]
Leon, A. C. S. [1 ]
Mahtani, R. [1 ]
Peereboom, D. M. [5 ]
机构：
[1] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[2] Florida Int Univ, Herbert Wertheim Coll Med, Miami, FL USA
[3] Univ Maryland Med, Dept Neurosurg, Baltimore, MD USA
[4] Baptist Hlth South Florida, Miami Neurosci Inst, Miami, FL USA
[5] Cleveland Clin, Cleveland, OH USA
来源：
NEURO-ONCOLOGY | 2024年 / 26卷
关键词：
D O I：
10.1093/neuonc/noae144.148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P06.11.A
引用
收藏
页码：V47 / V47
页数：1
相关论文
共 50 条
  • [11] Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
    Metzger Filho, O.
    Leone, J. P.
    Li, T.
    Tan-Wasielewski, Z.
    Trippa, L.
    Barry, W. T.
    Younger, J.
    Lawler, E.
    Walker, L.
    Freedman, R. A.
    Tolaney, S. M.
    Krop, I
    Winer, E. P.
    Lin, N. U.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1231 - 1239
  • [12] Tucatinib with Stereotactic Radiosurgery for HER2 Positive Brain Metastases: A Multi-Institutional Series
    Khatri, Vaseem
    Nakashima, Justyn
    Mills, Matthew
    Oliver, Daniel
    Yu, Michael
    Palmer, Joshua
    Perlow, Haley
    Mestres-Villanueva, Mariella
    Upadhyay, Rituraj
    Beyer, Sasha
    Ahmed, Kamran
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (10): : S11 - S11
  • [13] Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases
    Khatri, Vaseem M.
    Mestres-Villanueva, Mariella A.
    Yarlagadda, Sreenija
    Doniparthi, Ajay
    Smith, David B.
    Nakashima, Justyn Y.
    Bryant, John M.
    Zhao, Dekuang
    Upadhyay, Rituraj
    Mills, Matthew N.
    Oliver, Daniel E.
    Yu, Hsiang-Hsuan Michael
    Palmer, Joshua D.
    Williams, Nicole O.
    Mahtani, Reshma L.
    Ahluwalia, Manmeet S.
    Soliman, Hatem H.
    Han, Hyo S.
    Soyano, Aixa E.
    Kim, Youngchul
    Kotecha, Rupesh
    Beyer, Sasha J.
    Ahmed, Kamran A.
    NPJ BREAST CANCER, 2024, 10 (01)
  • [14] Tucatinib vs Placebo, Both Combined With Capecitabine and Trastuzumab, for Patients With Pretreated HER2-Positive Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 4 - 7
  • [15] Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
    Murthy, Rashmi
    Loi, Sherene
    Okines, Alicia
    Paplomata, Elisavet
    Hamilton, Erika
    Hurvitz, Sara
    Lin, Nancy
    Borges, Virginia
    Abramson, Vandana Gupta
    Anders, Carey
    Bedard, Philippe L.
    Oliveira, Mafalda
    Jakobsen, Erik
    Bachelot, Thomas
    Shachar, Shlomit S.
    Mueller, Volkmar
    Braga, Sofia
    Duhoux, Francois P.
    Greil, Richard
    Cameron, David
    Carey, Lisa
    Curigliano, Giuseppe
    Gelmon, Karen
    Hortobagyi, Gabriel
    Krop, Ian
    Loibl, Sibylle
    Pegram, Mark
    Slamon, Dennis
    Palanca-Wessels, Maria Corinna
    Walker, Luke
    Feng, Wentao
    Winer, Eric
    CANCER RESEARCH, 2020, 80 (04)
  • [16] Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
    Murthy, Rashmi
    Borges, Virginia F.
    Conlin, Alison
    Chaves, Jorge
    Chamberlain, Marc
    Gray, Todd
    Vo, Alex
    Hamilton, Erika
    LANCET ONCOLOGY, 2018, 19 (07): : 880 - 888
  • [17] Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)
    Lin, Nancy U.
    Murthy, Rashmi K.
    Abramson, Vandana
    Anders, Carey
    Bachelot, Thomas
    Bedard, Philippe
    Borges, Virginia
    Cameron, David
    Cameron, David
    Carey, Lisa
    Chien, A. Jo
    Curigliano, Giuseppe
    DiGiovanna, Michael
    Gelmon, Karen
    Hortobagyi, Gabriel
    Hurvitz, Sara
    Krop, Ian
    Loi, Sherene
    Loibl, Sibylle
    Mueller, Volkmar
    Oliveira, Mafalda
    Paplomata, Elisavet
    Pegram, Mark
    Slamon, Dennis
    Zelnak, Amelia
    Ramos, Jorge
    Feng, Wentao
    Winer, Eric
    CANCER RESEARCH, 2022, 82 (04)
  • [18] PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial
    Hu, Xichun
    Cao, Jun
    Teng, Yue'e
    Li, Hui-Ping
    Zhang, Lili
    Ouyang, Quchang
    Xie, Weimin
    Pan, Yueyin
    Song, Zhenchuan
    Ling, Xiaoling
    Wu, Xiaohong
    Xu, Jingwei
    Li, Li
    Ren, Liping
    Wang, Hong
    Zhou, Dongxian
    Luo, Jing
    CANCER RESEARCH, 2023, 83 (05)
  • [19] Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB)
    Curigliano, G.
    Murthy, R.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Cameron, D.
    Borges, V.
    Bedard, P.
    Oliveira, M.
    Jakobsen, E. H.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Carey, L. A.
    Loibl, S.
    Feng, W.
    Walker, L. N.
    Winer, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S62 - S63
  • [20] CLINICAL EFFICACY OF PYROTINIB COMBINING WITH STEREOTACTIC RADIOSURGERY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES
    Zhen, Juanjie
    Bashir, Shoaib
    Yang, Yanying
    Wang, Hui
    Lai, Mingyao
    Cai, Linbo
    NEURO-ONCOLOGY, 2024, 26
12345